Modern discloses details of covid-19 vaccine: 100% success

The race for the vaccine against the new coronavirus had a milestone on Tuesday. The modern pharmaceutical vaccine, one of the most promising in the world, was finally published in the prestigious New England Journal of Medicine.
The company's shares rose 16% after the close of trading on Tuesday with the release of the results of the study. Stocks had already quadrupled this year after vaccine testing began. At 7:30 a.m. on Wednesday, Modern's good result boosted the Dow Jones futures by 200 points and the Nasdaq and S&P 500 by 100 points.
In the publication, Moderna confirmed what had been expected since the first news broke two months ago. The vaccine is mostly safe and has generated immunization responses that can protect patients. The U.S. government's health authority said the findings support the importance of new and decisive testing phases.
The U.S. government has already shown interest in buying 300 million doses of vaccine in January 2021.
Moderna will now begin a test with 30,000 people starting on July 27 that will give the final answer whether the vaccine works or not.
Moderna was the first pharmaceutical company to do human trials and, with this news today, may be the first to commercially launch its product.
The company bets on its own line, using messenger RNA that would teach the human body to produce "blank" antibodies to prevent the virus before it actually starts the infection.